Ascendis Pharma (ASND) Tops Q1 EPS by 31c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR0.06), EUR0.31 better than the analyst estimate of (EUR0.37). Revenue for the quarter came in at EUR2.1 million versus the consensus estimate of EUR2.24 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• SanDisk upgraded at JPMorgan after investor day; shares climb